Corvus Pharmaceuticals, Inc.CRVSNASDAQ
LOADING
|||
Switch Symbol:
EPS Growth Accelerating
Trending higher, above historical average, slight contraction.
Left:
||||
Year-over-year earnings per share growth rate
Latest
-20.00%
↑ 19% above average
Average (39q)
-24.63%
Historical baseline
Range
High:378.79%
Low:-757.14%
CAGR
-3.9%
Modest growth trend
| Period | Value |
|---|---|
| Q3 2025 | -20.00% |
| Q2 2025 | -147.62% |
| Q1 2025 | 216.67% |
| Q4 2024 | 70.00% |
| Q3 2024 | -757.14% |
| Q2 2024 | 41.67% |
| Q1 2024 | 11.57% |
| Q4 2023 | -13.08% |
| Q3 2023 | 14.29% |
| Q2 2023 | 17.65% |
| Q1 2023 | 19.05% |
| Q4 2022 | 34.38% |
| Q3 2022 | -77.78% |
| Q2 2022 | 0.00% |
| Q1 2022 | 10.00% |
| Q4 2021 | 16.67% |
| Q3 2021 | 14.29% |
| Q2 2021 | 17.65% |
| Q1 2021 | -136.96% |
| Q4 2020 | 378.79% |
| Q3 2020 | 8.33% |
| Q2 2020 | 18.18% |
| Q1 2020 | -15.79% |
| Q4 2019 | -2.70% |
| Q3 2019 | 15.91% |
| Q2 2019 | -10.00% |
| Q1 2019 | -11.11% |
| Q4 2018 | 0.00% |
| Q3 2018 | 10.00% |
| Q2 2018 | 36.51% |
| Q1 2018 | -8.62% |
| Q4 2017 | 6.45% |
| Q3 2017 | 15.07% |
| Q2 2017 | 7.59% |
| Q1 2017 | -43.64% |
| Q4 2016 | -7.84% |
| Q3 2016 | -18.60% |
| Q2 2016 | 92.02% |
| Q1 2016 | -692.65% |
| Q4 2015 | -94.29% |